A lymph node biopsy report is organized around one central question: is the tissue normal, reactive (responding to infection or inflammation), or malignant (cancerous)? The pathologist’s conclusion usually appears at the very end of the document under a heading like “Diagnosis” or “Final Interpretation,” but the sections above it contain the evidence trail that led there. Understanding the vocabulary scattered through that trail can turn a bewildering document into something that actually makes sense, and can help you have a much more productive conversation with your doctor about what comes next.
The Anatomy of the Report
Most lymph node biopsy reports follow a roughly standard layout, though the exact formatting varies by hospital. At the top you’ll find patient identifiers, the specimen type (excisional biopsy, core needle biopsy, fine needle aspirate), and which lymph node was sampled. Below that sits the “Gross Description,” which is the pathologist’s account of what the tissue looked like with the naked eye: its size, shape, color, and texture. A node described as “tan-white, firm, and rubbery” sounds alarming, but that is fairly standard language even for benign tissue.
The “Microscopic Description” follows, and this is where the report gets dense. The pathologist describes what they saw under the microscope: the overall architecture of the node, the types of cells present, any unusual patterns, and results of special stains. Finally, the “Diagnosis” or “Interpretation” section states the conclusion. If additional testing was ordered, such as immunohistochemistry or molecular studies, those results may appear either within the microscopic section or in a separate addendum that arrives days later. That addendum can change the diagnosis, so a report that initially seems vague or incomplete may simply be awaiting further workup.
Reactive Versus Malignant: The First Fork in the Road
The single most important distinction on any lymph node biopsy is whether the findings are reactive or malignant. Reactive means the node is doing its job, mounting an immune response to an infection, a vaccination, an autoimmune process, or some other stimulus. Malignant means cancer cells are present, either a lymphoma that started in the node itself or a metastasis that spread there from somewhere else.
The tricky part is that reactive nodes can look dramatic under the microscope. Reactive follicular hyperplasia, in which the germinal centers (the zones where immune cells multiply and mature) enlarge and proliferate, sometimes mimics lymphoma closely enough that even experienced pathologists can be misled. In one study of solitary enlarged nodes with giant reactive follicles, half were initially misdiagnosed as lymphoma.1American Journal of Clinical Pathology. Reactive Lymph Node Hyperplasia with Giant Follicles Pathologists use several clues to tell the two apart. Reactive germinal centers tend to show “polarization,” meaning the dividing cells are arranged in an organized gradient, while neoplastic follicles lose that orderly pattern.2Clinics in Laboratory Medicine. How to Read Your Lymph Node Biopsy Results Stains like Ki-67 help highlight this polarization and are often mentioned in your report for exactly this reason.
If your report says “reactive lymphoid hyperplasia” or “follicular hyperplasia, no evidence of malignancy,” that is generally reassuring. It means the pathologist examined the tissue and concluded the enlarged node was an immune response, not cancer.
What Granulomatous Inflammation Means
Some reports describe “granulomas,” which are tight clusters of immune cells (particularly macrophages) that wall off substances the body can’t easily eliminate. If your report mentions granulomatous inflammation, the pathologist is flagging a specific pattern that narrows the list of possible diagnoses but doesn’t pinpoint one on its own.
Granulomas come in two broad flavors: necrotizing (with dead tissue in the center) and non-necrotizing (without). The distinction matters because the causes tend to cluster differently. In a large study of biopsies with granulomatous inflammation, non-necrotizing granulomas were found in about two-thirds of cases, and the most common cause was sarcoidosis. Among cases with necrotizing granulomas, tuberculosis was the leading cause.3PubMed Central. Diagnosis distribution in cases with granulomatous inflammation in lung, pleura, and lymph node biopsies But these categories aren’t airtight. Caseating (cheese-like necrosis) granulomas, traditionally associated with tuberculosis, also appear in a minority of sarcoidosis patients.4Cell Death & Disease. Neutrophil extracellular traps characterize caseating granulomas So the pathologist may describe the granuloma type and then list a differential diagnosis rather than naming a single cause. Additional tests, such as cultures for tuberculosis or fungal organisms, often follow.
When the Report Mentions Lymphoma
If your biopsy report raises the possibility of lymphoma, the terminology will shift noticeably. Instead of describing reactive patterns, the pathologist will describe abnormal cell populations, disrupted architecture, and the results of a panel of special stains used to classify the disease.
Architecture and Effacement
One of the first signs of lymphoma is disruption of the node’s normal internal structure. A healthy lymph node has distinct zones: a cortex, paracortex, and medulla, each populated by different immune cells.5PubMed. Normal structure, function, and histology of lymph nodes When lymphoma cells take over, they can partially or completely erase this architecture, a process the report calls “effacement.” Complete effacement means the normal zones are no longer recognizable. In cutaneous T-cell lymphoma, for example, pathologists grade lymph node involvement on a scale from scattered atypical cells in an otherwise preserved node up to total effacement by malignant cells.6Human Pathology. Histologic assessment of lymph nodes in mycosis fungoides/sézary syndrome Partial effacement can be harder to interpret because some reactive processes also distort architecture, which is why the pathologist leans heavily on stains and molecular testing to confirm the diagnosis.
Hodgkin Versus Non-Hodgkin Lymphoma
Your report will likely specify whether the lymphoma is Hodgkin or non-Hodgkin, and the distinction rests largely on one cell type. Classic Hodgkin lymphoma is defined by the presence of Reed-Sternberg cells, which are unusually large cells (sometimes reaching 100 micrometers across) with multiple nuclei or deeply lobed nuclei, each containing a prominent nucleolus.7Diagnostic Histopathology. Classical Hodgkin lymphoma and its differential diagnoses These cells sit within a characteristic inflammatory background of small lymphocytes, eosinophils, and other immune cells.
Confusingly, cells that look like Reed-Sternberg cells occasionally appear in non-Hodgkin lymphomas too. These lookalikes are called Reed-Sternberg-like cells, and pathologists distinguish them from the real thing by noting that they’re usually scattered and lack the classic inflammatory background of Hodgkin lymphoma.8PubMed Central. Hodgkin Reed-Sternberg-Like Cells in Non-Hodgkin Lymphoma Some reactive conditions can also produce large immunoblasts that mimic Reed-Sternberg cells, particularly in paracortical hyperplasia driven by a vigorous immune response.2Clinics in Laboratory Medicine. How to Read Your Lymph Node Biopsy Results This is why pathologists never diagnose Hodgkin lymphoma on cell appearance alone; they always confirm with immunohistochemistry.
What the Special Stains and Tests Mean
The microscopic description alone is often not enough to make a definitive diagnosis. Your report will likely mention immunohistochemistry (IHC), and possibly flow cytometry or molecular studies. These are the tests that turn a morphologic impression into a specific, actionable diagnosis.
Immunohistochemistry
IHC uses antibodies that bind to specific proteins on or in cells, then stains those proteins so the pathologist can see which cell types are present. You’ll see shorthand like “CD20+” or “CD3+” in the report. CD20 is a marker found on most B-cell lymphomas, while CD3 marks T-cell lymphomas. CD79a serves as a backup B-cell marker when CD20 is lost, which can happen after treatment with rituximab, a common lymphoma drug. Ki-67, which you may also see, measures how quickly cells are dividing; a higher percentage generally signals more aggressive disease.9PubMed Central. Basic immunohistochemistry for lymphoma diagnosis
A panel of these markers taken together creates a fingerprint for the type of lymphoma. For instance, a B-cell lymphoma that is CD20-positive, CD10-positive, and Bcl-2-positive with a low Ki-67 rate points strongly toward follicular lymphoma, while a different combination might point toward diffuse large B-cell lymphoma. The pathologist interprets this panel in context, so individual marker results in isolation don’t tell you much.
Flow Cytometry
If a fresh (unfixed) tissue sample was sent for flow cytometry, the report may include a separate flow cytometry section. This test suspends individual cells in a fluid stream and passes them past lasers, identifying the proteins on each cell’s surface. It’s especially useful for detecting “light chain restriction,” a hallmark of B-cell lymphomas. Normal B cells produce a mix of kappa and lambda light chains; when most B cells carry only one type, it suggests a clonal (malignant) population. However, flow cytometry isn’t infallible. In cases where surface light chain results are ambiguous, additional tests such as cytoplasmic light chain analysis or molecular clonality studies can improve accuracy, though molecular tests alone can sometimes mislead: in one study, about 15% of results were discordant with the true diagnosis.10PubMed Central. Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas?
Molecular and Cytogenetic Testing
Some reports include results from FISH (fluorescence in situ hybridization) or PCR (polymerase chain reaction) testing. These look for specific genetic changes associated with particular lymphoma types. FISH can detect chromosome translocations; the t(14;18) translocation, for example, is found in the vast majority of follicular lymphoma cases.11PubMed Central. The detection of t(14;18) in archival lymph nodes PCR can detect clonal rearrangements of immunoglobulin or T-cell receptor genes, helping confirm whether a suspicious cell population is truly monoclonal. These molecular results often arrive as addenda to the main report, sometimes a week or more later, and they can refine or even change the initial diagnosis.
Metastatic Disease in Lymph Nodes
Not all cancer found in a lymph node is lymphoma. When cancer from another organ, such as the breast, lung, or skin, spreads to a node, the report describes metastatic disease. The language here is quite different from a lymphoma report. Instead of describing the node’s own cells as abnormal, the pathologist identifies foreign tumor cells that don’t belong in lymph node tissue.
Sentinel Node Results and Tiny Deposits
If you had a sentinel lymph node biopsy, typically done for breast cancer or melanoma, the report will classify the findings in very specific terms. Macrometastases are deposits larger than 2 millimeters, micrometastases range from 0.2 to 2 millimeters, and isolated tumor cells (ITCs) are even smaller clusters or single cells. The staging significance of these categories differs. ITCs were once thought to be clinically insignificant, but a prospective study found that even these tiny deposits were associated with worse long-term outcomes. Ten-year distant disease-free survival was about 95% in patients without ITCs compared to roughly 89% in those with ITCs, and the presence of ITCs was an independent predictor of worse breast cancer-specific survival.12PubMed Central. Prognostic value of isolated tumour cells in sentinel nodes in early-stage breast cancer: a prospective study
Extranodal Extension
One term that carries significant weight in metastatic disease is “extranodal extension” (ENE), sometimes called “extracapsular spread.” This means cancer has grown through the lymph node’s outer capsule and into the surrounding tissue. ENE appears in your report as a prognostic red flag. In head and neck cancers, it is associated with higher rates of distant spread and poorer local control, and it is now formally incorporated into cancer staging guidelines for HPV-negative head and neck squamous cell carcinoma.13PubMed Central. Diagnostic challenges and prognostic implications of extranodal extension in head and neck cancer
In breast cancer, the picture is similar. Patients whose sentinel nodes showed extranodal extension had roughly a threefold increase in the risk of disease recurrence and were much more likely to have cancer in additional non-sentinel nodes.14Scientific Reports. Clinical significance of extranodal extension in sentinel lymph node positive breast cancer The extent of ENE matters too. Research has shown that when the perpendicular diameter of extranodal extension exceeds 3 millimeters, outcomes are independently worse, which means the pathologist’s measurement of ENE can directly influence treatment decisions.15PLOS ONE. Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer If your report mentions ENE, expect your oncologist to discuss more aggressive treatment options.
How Biopsy Type Affects What the Report Can Tell You
The type of biopsy performed shapes the quality and completeness of the results. An excisional biopsy, which removes the entire lymph node, gives the pathologist the most tissue to work with and preserves the node’s architecture. A core needle biopsy retrieves a small cylinder of tissue. A fine needle aspirate collects individual cells but little or no structural information.
For lymphoma diagnosis specifically, excisional biopsy remains the gold standard because architecture matters so much. A comparative analysis found that a diagnosis could be established in about 96% of excisional specimens after immunohistochemistry, compared to roughly 66% of core needle biopsies. Nearly 17% of core needle biopsies remained inconclusive even after IHC, partly because the small tissue samples were more prone to fragmentation and distortion.16PubMed. Comparative analysis on efficacy of lymph node sampling through whole node excision versus core needle biopsy That said, core needle biopsy can still be adequate in many situations. Another study found that over 92% of patients biopsied by core needle had sufficient diagnostic material to begin treatment without needing a second procedure.17PubMed Central. Should Core Needle Lymph Node Biopsy be a Relevant Alternative to Surgical Excisional Biopsy in Diagnostic Work Up of Lymphomas?
If your report is from a core needle biopsy and the diagnosis is listed as “inconclusive” or “atypical lymphoid proliferation, cannot exclude lymphoma,” it doesn’t necessarily mean something terrible was missed. It may mean the tissue sample was too small to make a confident call, and your doctor may recommend either a repeat biopsy or an excisional biopsy for a definitive answer.
When the Diagnosis Is Uncertain
Some of the most anxiety-producing reports are the ones that don’t give a clear answer. Phrases like “atypical lymphoid proliferation,” “cannot exclude lymphoma,” or “of uncertain significance” mean the pathologist sees something concerning but lacks enough evidence to make a definitive call. This is not a failure of the pathologist; it reflects the genuine difficulty of the tissue under review.
A striking example is Kikuchi-Fujimoto disease, a self-limited inflammatory condition that can closely mimic T-cell lymphoma. In one documented case, a patient’s biopsy was reviewed by four separate hematopathologists. While the clinical features favored Kikuchi-Fujimoto disease, the atypical T-cell proliferation left multiple experts unable to entirely rule out lymphoma.18American Journal of Clinical Pathology. Kikuchi-Fujimoto disease mimicking T-cell lymphoma after COVID-19 vaccination Cases like these illustrate why second opinions in hematopathology are not unusual and are perfectly reasonable to request. Progressive transformation of germinal centers is another benign condition that can alarm both patients and pathologists because it needs to be distinguished from nodular lymphocyte-predominant Hodgkin lymphoma.2Clinics in Laboratory Medicine. How to Read Your Lymph Node Biopsy Results
If your report lands in this gray zone, your doctor may recommend watchful waiting with a repeat biopsy in a few weeks, additional molecular testing, or referral to a specialized hematopathology center. The uncertainty is uncomfortable, but acting on an uncertain diagnosis can be worse than waiting for a clearer one.
Pediatric Lymph Node Biopsies Read Differently
If you’re reading a child’s biopsy report, the interpretive framework is not the same as for an adult. Children’s lymph nodes are more immunologically active at baseline, which means reactive changes tend to be more exuberant and can look more alarming on paper. A population of small, uniform-looking lymphocytes that might suggest low-grade B-cell lymphoma in an adult typically represents a reactive process in a child.19PubMed. Beyond the adult standard: Tailoring the WHO Reporting System for Lymph Node Cytopathology to pediatric diagnostics and management
Certain markers behave differently in children as well. TdT, a protein associated with immature lymphocytes and sometimes used as a marker for lymphoblastic lymphoma, is found at higher densities in normal pediatric lymph nodes than in adult ones.20Human Pathology. Benign TdT-positive cells in pediatric and adult lymph nodes A report that mentions scattered TdT-positive cells in a child’s node is not automatically alarming; it may simply reflect the higher baseline activity of a young immune system. Pathologists who specialize in pediatric cases calibrate their thresholds accordingly, and if your child’s biopsy was read at a general pathology lab, asking whether a pediatric hematopathology review would be useful is a reasonable question.
Rare Overlap Between Lymphoma and Metastatic Disease
Most lymph node biopsies will show either a lymphoma or a metastasis, not both. But it happens. In one case, a sentinel lymph node biopsy performed for suspected melanoma confirmed metastatic melanoma in multiple nodes, but those same nodes also showed background features of a low-grade lymphoma.21PubMed Central. Metastatic melanoma vs lymphoma. Using a sentinel lymph node biopsy a diagnostic tool Such coexistence is uncommon but illustrates why pathologists examine the entire tissue specimen rather than stopping once they find one abnormality. If your report mentions two separate diagnoses in the same node, each will typically be addressed independently in your treatment plan.